James Signorovitch

James Signorovitch

Auto-generated profile, based on publicly available information

James Signorovitch

Analysis Group Inc Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MFMirko Fillbrunn
Mirko Fillbrunn
JSJames Signorovitch
James Signorovitch
FAFabrice André
Fabrice André
IWIris Wang
Iris Wang
ILInes Lorenzo
Ines Lorenzo
HRHope S. Rugo
Hope S. Rugo
Background: Approximately 40% of hormone receptor positive/human epidermal receptor 2 negative (HR + /HER2-) metastatic breast cancer (mBC) patients harbor phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations. However, associations between PIK3CA mutation status and clinical outcomes among patients with HR + /HER2- mBC have been heterogeneous across clinical trials. This meta-analysis was conducted to survey recently available trial data to assess the prognostic effects of PIK3CA among patients with HR + /HER2- mBC. Methods: Randomized clinical trials reporting progression-free survival (PFS) or overall survival (OS) stratified by PIK3CA status in HR + /HER2- mBC were identified via systematic literature review. Trial arms receiving phosphatidylinositol 3-kinase (PI3K)-targeted therapies were excluded. Meta-regression analysis was used to estimate the association between PIK3CA status and PFS and OS among included studies. Results: The analyzed data included 3,219 patients from 33 study arms across 11 trials (PIK3CA mutated: 1,386, wild type: 1,833). PIK3CA mutation was associated with shorter median PFS (difference [95% CI] (months): -1.8 [-3.4, -0.1], I2 = 35%) and shorter median OS (-8.4 [-13.4, -3.5], I2 = 58%, N = 1,545). Findings were similar for PFS rates at 6 months (odds ratio [95% CI]: 0.74 [0.59, 0.94], I2 = 42%, N = 3,160) and 12 months (0.76 [0.59, 0.99], I2 = 42%, N = 2,468) and directionally consistent but not statistically significant at 18 months (N = 1,726). Conclusions: Pooling evidence across multiple studies, PIK3CA mutation was associated with shorter PFS and OS. These findings suggest a negative prognostic value of PIK3CA mutations in patients with HR + /HER2- mBC.

10 October 2019 in Muscle & Nerve
Verified
Journal Article
Open access
PDF file
CMCraig M. McDonald
Craig M. McDonald
GSGautam Sajeev
Gautam Sajeev
ZYZhiwen Yao
Zhiwen Yao
EMErin McDonnell
Erin McDonnell
GEGary Elfring
Gary Elfring
FGfor the ACT DMD Study Group and the Tadalafil DMD Study Group
for the ACT DMD Study Group and the Tadalafil DMD Study Group
Introduction: In this study we characterized disease progression over 48 weeks among boys receiving deflazacort vs prednisone/prednisolone placebo arm treatment in two recent Duchenne muscular dystrophy (DMD) clinical trials.Methods: Ambulatory boys with DMD receiving placebo in the phase 3 ataluren (N = 115) and tadalafil (N = 116) trials were included. The trials required at least 6 months of prior corticosteroid use and stable baseline dosing. Associations between corticosteroid use and 48‐week changes in ambulatory function were estimated using mixed models. Adjusted differences between corticosteroid groups were pooled in a meta‐analysis.Results: In the meta‐analysis, deflazacort‐treated patients vs prednisone/prednisolone‐treated patients experienced, on average, lower declines of 28.3 meters on 6‐minute walk distance (95% confidence interval [CI], 5.7, 50.9; 2.9 seconds on rise from supine [95% CI, 0.9, 4.9 seconds]; 2.3 seconds on 4‐stair climb [95% CI, 0.5, 4.1 seconds]; and 2.9 [95% CI, 0.1, 5.8] points on the North Star Ambulatory Assessment linearized score).Discussion: Deflazacort‐treated patients experienced significantly lower functional decline over 48 weeks.

1 October 2015 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
TVTimothy Vollmer
Timothy Vollmer
JSJames Signorovitch
James Signorovitch
LHLynn Huynh
Lynn Huynh
PGPhilip Galebach
Philip Galebach
CKCaroline Kelley
Caroline Kelley
RSRahul Sasane
Rahul Sasane

4 November 2015 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
TVTimothy Vollmer
Timothy Vollmer
LHLynn Huynh
Lynn Huynh
CKCaroline Kelley
Caroline Kelley
PGPhilip Galebach
Philip Galebach
JSJames Signorovitch
James Signorovitch
RSRahul Sasane
Rahul Sasane

11 April 2023 in Neurology
Verified
Journal Article
Open access
PDF file
FMFrancesco Muntoni
Francesco Muntoni
JSJames Signorovitch
James Signorovitch
GSGautam Sajeev
Gautam Sajeev
HLHenry Lane
Henry Lane
MJMadeline Jenkins
Madeline Jenkins
AAAnnemieke Aartsma-Rus
Annemieke Aartsma-Rus
Background and Objectives: Clinical trials of genotype-targeted treatments in Duchenne muscular dystrophy (DMD) traditionally compare treated patients to untreated patients with the same DMD genotype class. This avoids confounding of drug efficacy by genotype effects but also shrinks the pool of eligible controls, increasing challenges for trial enrollment in this already rare disease. To evaluate the suitability of genotypically unmatched controls in DMD, we quantified effects of genotype class on 1-year changes in motor function endpoints used in clinical trials. Methods: Over 1,600 patient-years of follow-up (>700 patients) were studied from six real-world/natural history data sources (UZ Leuven, PRO-DMD-01 shared by CureDuchenne, iMDEX, North Star UK, Cincinnati Children’s Hospital Medical Center, and the DMD Italian Group), with genotypes classified as amenable to skipping exons 44, 45, 51 or 53, other skippable, nonsense, and other mutations. Associations between genotype class and 1-year changes in North Star Ambulatory Assessment total score (ΔNSAA) and in 10-meter walk/run velocity (Δ10MWR) were studied in each data source with and without adjustment for baseline prognostic factors. Results: The studied genotype classes accounted for approximately 2% of variation in ΔNSAA outcomes after 12 months, whereas other prognostic factors explained >30% of variation in large data sources. Based on a meta-analysis across all data sources, pooled effect estimates for the studied skip-amenable mutation classes were all small in magnitude (<2 units in ΔNSAA total score in 1-year follow up), smaller than clinically important differences in NSAA, and were precisely estimated with standard errors <1 unit after adjusting for non-genotypic prognostic factors. Discussion: These findings suggest viability of trial designs incorporating genotypically mixed or unmatched controls for up to 12 months in duration for motor function outcomes, which would ease recruitment challenges and reduce numbers of patients assigned to placebos. Such trial designs, including multi-genotype platform trials and hybrid designs, should ensure baseline balance between treatment and control groups for the most important prognostic factors, while accounting for small remaining genotype effects quantified in the present study.

26 April 2022 in Journal of Medical Economics
Verified
Journal Article
Open access
KKKalé Kponee-Shovein
Kalé Kponee-Shovein
JMJessica Marvel
Jessica Marvel
RIRyotaro Ishikawa
Ryotaro Ishikawa
ACAbhay Choubey
Abhay Choubey
HKHarneet Kaur
Harneet Kaur
JSJames Signorovitch
James Signorovitch
Asthma exacerbations are a primary driver of costs and health impacts from asthma. Despite research suggesting that asthma care has a disproportionate carbon footprint, emissions costs are not cons...